Pfizer (PFE) Sees Approval of MRNA Flu Vaccine in 2024 - Bloomberg, Citing Presentation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Pfizer (PFE) stock can outperform even in a 'trough COVID' scenario says Goldman Sachs
January 10, 2023 1:43 PM ESTPfizer (NYSE: PFE) management presented at an investor conference yesterday its Chief Executive Albert Bourla said to have reiterated plans for shaping Pfizer post-Covid.
Following the Pfizer presentation, Credit Suisse analyst Trung Huynh told investors in a note that Pfizer focused on the non-Covid side of the business.
"For the non-COVID sales, Dr. Bourla reiterated its 2020-25 mid-term guide of +6% and also first-time longer-term 2025-30 guidance of 6-10%, which comes in ahead of consensus expectations," wrote Huynh, who maintained... More
